<DOC>
	<DOCNO>NCT02104245</DOCNO>
	<brief_summary>This study ( ARD-3150-1201 , ORBIT-4 ) evaluate safety efficacy inhale Pulmaquin compare inhale placebo subject confirm diagnosis non-cystic fibrosis ( non-CF ) bronchiectasis history pulmonary exacerbation chronic P. aeruginosa infection .</brief_summary>
	<brief_title>Phase 3 Study With Dual Release Ciprofloxacin Inhalation Non-CF Bronchiectasis</brief_title>
	<detailed_description>This multinational , multicenter , randomize , double-blind , placebo-controlled study evaluate safety efficacy Pulmaquin compare placebo management chronic lung infection P. aeruginosa subject non-CF bronchiectasis history pulmonary exacerbation . This study consist Screening Phase , Double-Blind Phase ( 6 cycle consist 28-days daily Pulmaquin Placebo , 28 day treatment ) follow Open-Label Extension ( 28 day Pulmaquin ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Confirmed diagnosis nonCF bronchiectasis History P. aeruginosa respiratory infection At least two pulmonary exacerbation treat antibiotic previous year Have clinical diagnosis CF Are pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Non Cystic Fibrosis Bronchiectasis , Pulmaquin , Ciprofloxacin , Pseudomonas aeruginosa</keyword>
</DOC>